Vernonia amygdalina upregulates hepatic enzymes and improves liver microanatomy in experimental diabetes mellitus

Pharmacologyonline

Volumn 2, Issue , 2009, Pages 1231-1242

  Akinola, Oluwafunmike S ^a   Akinola, Oluwole B ^a   Caxton Martins, Ezekiel A ^a  

^a UNIVERSITY OF ILORIN   (Nigeria)

Author keywords

Glucose 6 phosphate dehydrogenase; Lactate dehydrogenase; Liver; Vernonia amygdalina

Indexed keywords

ALCOHOL; CHLORPROPAMIDE; GLUCOSE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; LACTATE DEHYDROGENASE; LIVER ENZYME; STREPTOZOCIN; VERNONIA AMYGDALINA EXTRACT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ACTIVITY; ENZYME ACTIVITY; FEMALE; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER CELL; LIVER SINUSOID; LIVER STRUCTURE; LIVER WEIGHT; MALE; MICROSCOPIC ANATOMY; MONOTHERAPY; NONHUMAN; PLANT LEAF; RAT; UPREGULATION; VENOUS CONGESTION; WISTAR RAT;

EID: 70349623960     PISSN: None     EISSN: 18278620     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Dham S, Shah V, Hirsch S, Banerji MA. The role of complementary and alternative medicine in diabetes. Current Diabetes Reports 2006; 6: 251-258.
2. Ebong PE, Atangwho IJ, Eyong, Egbung GE. The Antidiabetic Efficacy of Combined Extracts from Two Continental Plants: Azadirachta indica (A. Juss) (Neem) and Vernonia amygdalina (Del.) (African Bitter Leaf). Am. J. Biochem. Biotechnol. 2008; 4: 239-244.
3. Torbenson M, Chen Y, Brunt E, Cummings OW, Gottfried M, Jakate S, Liu Y, Yeh MM, Ferrell L. Glycogenic hepatopathy: an underrecognised hepatic complication of diabetes mellitus. Am. J. Surg. Pathol. 2006; 30: 508-513.
4. Clark JM, Diehl AM. Hepatic steatosis and type 2 diabetes mellitus. Current Sci. 2002; 2: 210-215.
5. Nishikawa T, Edelstein D, Du XL. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000; 404: 787-90.
6. Blakytny R, Harding JJ. Glycation (non-enzymatic glycosylation) inactivates glutathione reductase. Biochem J. 1992; 288: 303-307.
7. Yoshida K, Hirokawa J, Tagami S, Kawakami Y, Urata Y, Kondo T. Weakened cellular scavenging activity against oxidative stress in diabetes mellitus: regulation of glutathione synthesis and efflux. Diabetologia 1995; 38: 201-210.
8. Cramer CT, Cookie S, Ginsberg LC, Kletzien RF, Stapleton SR, Ulrich RG. Upregulation of glucose 6-phosphate dehydrogenase in response to hepatocellular oxidative stress: studies with diquat. J. Biochem. Toxicol. 2006; 10: 293-298.
9. Halliwell B, Gutteridge JM. Free radicals in biology and medicine. Clarendon, Oxford, UK. 1989.
10. Kirkman HN, Rolfo M, Ferraris AM, Gactani GF. Mechanisms of protection of catalase by NADPH. J. Biol. Chem. 1999; 274: 13908-13914.
11. Arit E, Olorunfemi AE, Amaku OI, Edoho JE. Studies of some effects of Vernonia amygdalina in rats. Asian J. Biochem. 2007; 2: 193-197.
12. Nwanjo HU. Efficacy of aqueous leaf extract Vernonia amygdalina on plasma lipoprotein and oxidative status in diabetic rat models. Nigr. J. Physiol. Sci. 2005; 20: 39-42
13. Lenzen S. The mechanism of alloxan- and streptozotocin-induced diabetes. Diabetologia 2008; 51: 216-226.
14. Gupta S, Kataria M, Gupta PK, Murganandan S, Yashroy RC. Protective role of extract of neem seeds in diabetes caused by streptozotocin in rats. J. Ethnopharmacol. 2004; 90: 185-189.
15. Yousef MI, Haroun M, El-Masry MH, Ateia REA. Biochemical and immunological study of Barley and its components as hypoglycemic agents in diabetic rats. Am. J. Biochem. Biotechnol. 2006; 2: 1-8.
16. Sathishsekar D, Subramanian S. Beneficial effects of Momordica charantia seeds in the treatment of STZ-induced diabetes in experimental rats. Biol. Pharm. Bull. 2005; 28: 978-983.
17. Weisshaar HD, Sudhoff H, Koller PU, Bablok W. Reference values for lactate dehydrogenase in the serum during childhood. Med. Welt. 1975; 26: 387.
18. Lohr GW, Waller HD. Glucose 6 phosphate dehydrogenase. Methods of enzymatic analysis, 3rd edition. Varlag Chemie, Weinheim. 1974. Pg 636
19. Akah PA, Okafor CL. Blood sugar lowering effect of Vernonia amygdalina Del in an experimental rabbit model. Phytother. Res. 2006; 6: 171-173.
20. Ezekwe CI, Obidoa O. Biochemical effect of Vernonia amygdalina on rat liver microsomes. Nigr J Biochem Mol Biol. 2001; 16: 1745-1798.
21. Igile GO, Oleszek W, Jurzysta M et al. Flavonoids from Vernonia amygdalina and their antioxidant activities. J Agric Food Chem. 1994; 42: 2445- 2448.
22. Jisaka M, Ohigashi H, Takagaki T et al. Bitter Steroid Glucosides, Vernoniosides A1, A2, and A3 and related B1 from a possible medicinal plant Vernonia amygdalina used by wild chimpanzees. Tetrahedron 1992; 48: 625-632
23. Erasto P, Grierson DS, Afolayan AJ. Bioactive sesquiterpene lactones from the leaves of Vernonia amygdalina. J Ethnopharmacol. 2006; 106: 117-120.
24. Adewole SO, Ojewole JA, Caxton-Martins EA. Protective effects of quercetin on the morphology of pancreatic β cells of streptozotocin-treated diabetic rats. Afr. J. Traditional Compl. Alternative Med. 2007; 4: 64-74.
25. Adewole SO, Caxton-Martins EA. Morphological and hypoglycaemic effects of Annona muricata Linn (Annonaceae) leaf aqueous extract on pancreatic B cells of streptozotocin-treated diabetic rats. Afr. J. Biomed. Res 2006; 9: 173-187.
26. Ojewole JAO. Antinociceptive, anti-inflammatory and antidiabetic effects of Bryophyllum pinnatum (Crassulaceae) leaf aqueous extract. J. Ethnopharmacol. 2005; 99: 13-19
27. Katzung BG. Basic and Clinical Pharmacology, 10th edition, McGraw-Hill, Singapore, 2007. pg 683-705.
28. Baquer NZ, Gupta D, Raju J. Regulation of metabolic pathway in liver and kidney during experimental diabetes. Effects of antidiabetic compounds. Ind. J. Clin. Biochem. 1998; 13: 63-80.
29. Mehta AB. Glucose-6-phosphate dehydrogenase deficiency. Postgrad. Med. J. 1994; 70, 871-877.
30. Baskin DG, Lattemann DF, Seeley RJ et al. Insulin and leptin: dual adiposity signals to the brain for the regulation of food intake and body weight. Brain Res. 1999; 848: 114-123.
31. Szayna M, Doyle ME, Betkey JA et al. Exendin-4 decelerates food intake, weight gain and fat deposition in Zucker rats. Endocrinol. 2000; 141: 1936-1941.
32. Bjorbaek C, Elmquist JK, Frantz JD, Shoelson SE, Flier JS. Identification of SOCS-3 as a potential mediator of central leptin resistance, Mol. Cell 1998; 1; 619-625.
33. Martocchia A, Risicato MG, Mattioli MA, Ruco L, Falaschi P. Association of diffuse liver glycogenosis and mild focal macrovesicular steatosis in a patient with poorly controlled type 1 diabetes. Intern. Emerg. Med. 2008; 3: 273-274.
34. Stone BE, Van Thiel DH. Diabetes mellitus and the liver. Semin. Liver Dis. 1985; 5: 8-28.
35. Munns CF, McCrossin RB, Thomsett MJ, Batch J. Hepatic glycogenosis: reversible hepatomegaly in type 1 diabetes. J. Paediatr. Child Health 2000; 36: 449-452.
36. Mauriac P. 'Gros ventre, hepatomegaly, troubles de la croissance chez les enfants diabetiques, traits depuis plusieurs anbnees par l'insuline'. Gas Hebd Sci. Med. Bordeaux 1930; 51: 402.
37. Ozen H. Glycogen storage diseases: new perspectives. World J. Gastroenterol. 2007; 13: 2541-2553.
38. Iancu TC, Shiloh H, Dembo L. Hepatomegaly following short-term high-dose steroid therapy. J Paediatr Gastroenterol. Nutr. 1986; 5: 41-46.
39. Khandelwal RL, Zinman SM, Zebrowski EJ. The effect of STZ-induced diabetes and of insulin supplementation on glycogen metabolism in rat liver. Biochem. J. 1977; 168: 541-548.
40. Bahnak BR, Gold AH. Effects of alloxan diabetes on the turnover of rat liver glycogen synthase. J. Biol. Chem. 1982; 257: 8775-8780.
41. Ferrannini F, Lanfranchia A, Rohner-Jfanrenaud F, Manfredini G, Vandewerve V. Influence of long-term diabetes on liver glycogen metabolism in rat. Metab. 1990; 39: 1082-1088.